Min-Chun Chen

Min-Chun Chen

Auto-generated profile, based on publicly available information

Min-Chun Chen

Department of Pharmacy, Xi’an No.3 Hospital, the Affiliated Hospital of Northwest University, Xi’an, China

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
MCMinchun Chen
Minchun Chen
SXSuqiang Xiong
Suqiang Xiong
JZJie Zheng
Jie Zheng
JZJingyi Zhang
Jingyi Zhang
DYDan Ye
Dan Ye
KYKangkang Yan
Kangkang Yan

20 October 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MWMingming Wang
Mingming Wang
MCMinchun Chen
Minchun Chen
YDYi Ding
Yi Ding
ZZZhihui Zhu
Zhihui Zhu
YZYikai Zhang
Yikai Zhang
AWAidong Wen
Aidong Wen
Vascular endothelial cells play an important role in modulating anti-thrombus and maintaining the natural function of vascular by secreting many active substances. β-boswellic acid (β-BA) is an active triterpenoid compound from the extract of boswellia serrate. In this study, it is demonstrated that β-BA ameliorates plasma coagulation parameters, protects endothelium from blood stasis induced injury and prevents blood stasis induced impairment of endothelium-dependent vasodilatation. Moreover, it is found that β-BA significantly increases nitric oxide (NO) and cyclic guanosine 3’, 5’-monophosphate (cGMP) levels in carotid aortas of blood stasis rats. To stimulate blood stasis-like conditionsin vitro, human umbilical vein endothelial cells (HUVECs) were exposed to transient oxygen and glucose deprivation (OGD). Treatment of β-BA significantly increased intracellular NO level. Western blot and immunofluorescence as well as immunohistochemistry reveal that β-BA increases phosphorylation of enzyme nitric oxide synthase (eNOS) at Ser1177. In addition, β-BA mediated endothelium-dependent vasodilatation can be markedly blocked by eNOS inhibitor L-NAME in blood stasis rats. In OGD treated HUEVCs, the protective effect of β-BA is attenuated by knockdown of eNOS. In conclusion, the above findings provide convincing evidence for the protective effects of β-BA on blood stasis induced endothelial dysfunction by eNOS signaling pathway.

1 February 1992 in Southern Medical Journal
Verified
Journal Article
Closed access
MCMin-Chun Chen
Min-Chun Chen
MKMabel Koshy
Mabel Koshy
JKJohn Kennedy
John Kennedy
We have described a a 23-year-old black woman with sickle cell beta-thalassemia who had a urinary tract infection and who was incidentally found to be pancytopenic. Although her anemia was categorized as "normocytic, normochromic" by an electronic particle counter, evaluation of the pancytopenia confirmed unsuspected pernicious anemia. Greater vigilance and a higher index of suspicion are crucial for early diagnosis of pernicious anemia in patients with other known hemoglobinopathies.

1 August 2005 in Oncology
Verified
Journal Article
Closed access
PDF file
JYJames Chih-Hsin Yang
James Chih-Hsin Yang
MCMin-Chun Chen
Min-Chun Chen
LCLi-Tzong Chen
Li-Tzong Chen
CHChih-Hung Hsu
Chih-Hung Hsu
KYKun-Huei Yeh
Kun-Huei Yeh
PYPan-Chyr Yang
Pan-Chyr Yang
Objective: High-dose epirubicin was shown to be effective in the treatment of inoperable non-small cell lung cancer (NSCLC). Paclitaxel is synergistic to a conventional dose of anthracyclines in the treatment of advanced cancer. A phase II study was designed to test the effectiveness of combining paclitaxel with a conventional dose of epirubicin in inoperable NSCLC patients. Methods: Eligibility criteria included inoperable stage IIIB or IV NSCLC patients, Eastern Cooperative Oncology Group performance status of 0–2, measurable or evaluable disease and adequate organ function. Epirubicin 70 mg/m2 intravenous infusion for 15 min was given on day 1. Paclitaxel 175 mg/m2 intravenous infusion for 3 h was given on day 2. Cycles were repeated every 21 days. Tumor response was evaluated every two cycles. Patients received treatment until disease progression, unacceptable toxicity or stable disease after cycle 6. Results: Thirty-eight patients received a total of 185 cycles (median 6 cycles). Seventeen patients responded to treatment (response rate 44.7%). Twenty-six (68%) patients received second-line chemotherapy. All patients were followed until their death. Median survival was 11.9 months (95% confidence interval 9.0–14.9 months). Median time-to-treatment-failure was 4.6 months. Conclusion: Conventional dose epirubicin plus paclitaxel is effective as a first-line treatment for inoperable NSCLC patients.

1 June 1990 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
MCMin-Chun Chen
Min-Chun Chen
MMMichael R. Mullane
Michael R. Mullane

1 August 1993 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
WHWen‐Li Hwang
Wen‐Li Hwang
JGJyh‐Ping Gau
Jyh‐Ping Gau
MCMin‐Chun Chen
Min‐Chun Chen
JYJi‐Hsiung Young
Ji‐Hsiung Young
Click on the article title to read more.